The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 999
Berget, C., Sherr, J. L., DeSalvo, D. J., KINGMAN, R. S., Stone, S. L., Brown, S. A., Nguyen, A., Barrett, L., Ly, T. T., & Forlenza, G. P. (2021) · Clinical Diabetes · doi:10.2337/cd21-0083 · Cited by 39
Self-citationRecent trends and advances in type 1 diabetes therapeutics: A comprehensive review
Singh, A. K., Afshan, N., Singh, A., Singh, S. K., Yadav, S., Kumar, M., Sarma, D. K., & Verma, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151329 · Cited by 43
Dovč, K., Bergford, S., Fröhlich-Reiterer, E. E., Zaharieva, D. P., Potočnik, N., Müller, A., Lenarčič, Ž., Calhoun, P. M., Fritsch, M., Sourij, H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0178 · Cited by 43
Self-citationMontaser, E., Farhy, L. S., & Kovatchev, B. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae379 · Cited by 45
Self-citationPractical implementation of automated closed-loop insulin delivery: A French position statement
Tubiana‐Rufi, N., Schaepelynck, P., Franc, S., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.10.004 · Cited by 42
Flatt, A. J., Peleckis, A. J., DALTON-BAKES, C. V., Nguyen, H.-L., Ilany, S., MATUS, A. M., Malone, S. K., Goel, N., Jang, S., Weimer, J. E., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0506 · Cited by 40
Jacobs, P. G., Resalat, N., Hilts, W. W., Young, G. M., LEITSCHUH, J. A., Pinsonault, J., Youssef, J. E., Branigan, D. L., Gabo, V. B., Eom, J. H., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00112-7 · Cited by 45
Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes
Marks, B. E., Meighan, S. S., Zehra, A., Douvas, J. L., Rearson, A., Suresh, R., Brown, E. A., & Wolf, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0337 · Cited by 39
New and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 46
Addala, A., Suttiratana, S. C., Wong, J. J., Lanning, M. S., Barnard, K. D., Weissberg-Benchell, J. A., Laffel, L. M., Hood, K. K., & Naranjo, D. M. (2021) · Diabetic Medicine · doi:10.1111/dme.14575 · Cited by 38
Self-citationAuzanneau, M., Rosenbauer, J., Maier, W., von Sengbusch, S., Hamann, J., Kapellen, T. M., Freckmann, G., Schmidt, S., Lilienthal, E., & Holl, R. W. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211028608 · Cited by 38
Janež, A., Battelino, T., Klupa, T., Kocsis, G., Kuricova, M., Lalic, N. M., Stoian, A. P., Prázný, M., Rahelić, D., Šoupal, J., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01160-5 · Cited by 44
Bionic Pancreas Research Group, Kruger, D., Kass, A., Lonier, J., Pettus, J., Raskin, P., Salam, M., Trikudanathan, S., Zhou, K., Russell, S. J., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0200 · Cited by 38
Self-citationLevy, C. J., Raghinaru, D., Kudva, Y. C., Pandit, K., Blevins, T., Casaubon, L., Desjardins, D., Levister, C. M., O’Malley, G., Reid, C., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0025 · Cited by 37
Self-citationBoucsein, A., Watson, A. S., Frewen, C. M., Sanders, O. J., Haszard, J. J., Jones, S. D., Milford-Hughes, P. J., de Bock, M. I., & Wheeler, B. J. (2023) · Diabetes Care · doi:10.2337/dc22-1971 · Cited by 40
Scully, K. J., Palani, G., Zheng, H., Moheet, A. A., & Putman, M. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0354 · Cited by 38
A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes
Donovan, L., Feig, D. S., Lemieux, P., Murphy, H. R., Bell, R. C., Sigal, R. J., Ho, J., Virtanen, H., Crawford, S. G., & Yamamoto, J. M. (2023) · Diabetes Care · doi:10.2337/dc23-0882 · Cited by 37
Kovatchev, B. P., Castillo, A., Pryor, E. C., Kollar, L. L., Barnett, C. L., DeBoer, M. D., Brown, S. A., & for the NAP Study Team (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0469 · Cited by 43
Self-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes
Rachid, O., Osman, A., Abdi, R., & Haik, Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1727885 · Cited by 38
Thomas, C., Welsh, J. B., Lu, S., & Gray, J. M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820920948 · Cited by 37
Noor, N., Kamboj, M. K., Triolo, T. M., Polsky, S., McDonough, R., Demeterco‐Berggren, C., Jacobsen, L. M., Sonabend, R., Ebekozien, O. A., & DeSalvo, D. J. (2022) · Diabetes Care · doi:10.2337/dc22-0329 · Cited by 37
A meta-learning approach to personalized blood glucose prediction in type 1 diabetes
Langarica, S., Rodriguez-Fernández, M., Núñez, F., & Doyle, F. J. (2023) · Control Engineering Practice · doi:10.1016/j.conengprac.2023.105498 · Cited by 37
Self-citationCarbohydrate Intake in the Context of Exercise in People with Type 1 Diabetes
Scott, S. N., Kempf, P., Bally, L., & Stettler, C. (2019) · Nutrients · doi:10.3390/nu11123017 · Cited by 45
Burnside, M. J., Lewis, D. M., Crocket, H. R., Wilson, R., Williman, J. A., Jefferies, C., Paul, R. G., Wheeler, B. J., & de Bock, M. I. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00547-8 · Cited by 36
Sofizadeh, S., Pehrsson, A., Ólafsdóttir, A. F., & Lind, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820965599 · Cited by 36
Bode, B. W., Carlson, A. L., Liu, R., Hardy, T. A., Bergenstal, R. M., Boyd, J., Morrett, S., & Ignaut, D. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0184 · Cited by 38
A Data-Driven Approach to Classifying Daily Continuous Glucose Monitoring (CGM) Time Series
Lobo, B. J., Farhy, L. S., Shafiei, M., & Kovatchev, B. P. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3103127 · Cited by 36
Self-citationCurrent Management of Glycemia in Children with Type 1 Diabetes Mellitus
Sperling, M. A., & Laffel, L. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2112175 · Cited by 37
Self-citationAutomated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes
Garcia‐Tirado, J., Farhy, L. S., Nass, R. M., Kollar, L. L., Oliveri, M. C., Basu, R., Kovatchev, B. P., & Basu, A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0542 · Cited by 37
Self-citationA Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell–derived Islets
Ramzy, A., Belmonte, P. J., Braam, M. J. S., Ida, S., Wilts, E. M., Levings, M. K., Rezania, A., & Kieffer, T. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac021 · Cited by 37
Haidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jafar, A., Devaux, M., Ghanbari, M., & RABASA-LHORET, R. P. R. (2023) · Diabetes Care · doi:10.2337/dc22-2297 · Cited by 38
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Messer, L. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0308 · Cited by 36
Nanomedicine in the Treatment of Diabetes
Andreadi, A., Lodeserto, P., Todaro, F., Meloni, M., Romano, M., Minasi, A., Bellia, A., & Lauro, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137028 · Cited by 35
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
Lind, M., Ólafsdóttir, A. F., Hirsch, I. B., Bolinder, J., Dahlqvist, S., Pivodic, A., Hellman, J., Wijkman, M. O., Schwarcz, E., Albrektsson, H., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1468 · Cited by 35
MCVEAN, J. J. F., & Miller, J. D. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1926984 · Cited by 37
A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes
Bassi, M., Teliti, M., Lezzi, M., Iosca, A., Strati, M. F., Carmisciano, L., d’Annunzio, G., Minuto, N., & Maggi, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802419 · Cited by 35
Emmert‐Streib, F., & Yli-Harja, O. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113149 · Cited by 38
Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics
Curreri, A. M., Kim, J., Dunne, M., Angsantikul, P., Goetz, M. J., Gao, Y., & Mitragotri, S. (2023) · Advanced Science · doi:10.1002/advs.202205389 · Cited by 37
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
Closed-loop bioelectronic medicine for diabetes management
Güemes, A., Etienne‐Cummings, R., & Georgiou, P. (2020) · Bioelectronic Medicine · doi:10.1186/s42234-020-00046-4 · Cited by 34
Clinical characteristics and management of type 1 diabetes in Spain. The SED1 study
Peralta, F. G., Torre, E. L. M., Conde, S., Conget, I., & Novials, A. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.11.020 · Cited by 34
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 39
Self-citationReznik, Y., Carvalho, M., Fendri, S., Prevost, G., Chaillous, L., Riveline, J. P., Hanaire, H., Dubois, S., Houéto, P., Pasche, H., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15351 · Cited by 34
Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
Kim, J. Y., Yoo, J. H., & Kim, J. H. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0264 · Cited by 33
Vigersky, R. A., & Shin, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0435 · Cited by 33
Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c
Boucsein, A., Zhou, Y., Michaels, V. R., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400185 · Cited by 34
MOSQUERA-LOPEZ, C. M., & Jacobs, P. G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211042621 · Cited by 37
Benhamou, P., Adenis, A., Tourki, Y., Pou, S., Madrolle, S., Franc, S., Kariyawasam, D., Beltrand, J., Klonoff, D. C., & Charpentier, G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221128565 · Cited by 33
Burnside, M. J., Lewis, D. M., Crocket, H. R., Meier, R. A., Williman, J. A., Sanders, O. J., Jefferies, C., Faherty, A. M., Paul, R. G., Lever, C. S., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0484 · Cited by 33
Aiello, E. M., Jaloli, M., & Cescon, M. (2023) · Control Engineering Practice · doi:10.1016/j.conengprac.2023.105810 · Cited by 32
Stahl‐Pehe, A., Mashhadi, N. S., Wirth, M., Schlesinger, S., Kuß, O., Holl, R. W., Bächle, C., Warz, K.-D., Bürger-Büsing, J., Spörkel, O., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103190 · Cited by 38
Schoelwer, M. J., Robic, J. L., Gautier, T., Fabris, C., Carr, K., Oliveri, M. C., Brown, S. A., Anderson, S. M., DeBoer, M. D., Cherñavvsky, D. R., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0471 · Cited by 32
Self-citationArtificial Intelligence Algorithms for Treatment of Diabetes
Rashid, M. M., Askari, M. R., Chen, C., Liang, Y., Shu, K., & Çınar, A. (2022) · Algorithms · doi:10.3390/a15090299 · Cited by 35
The role of machine learning in advancing precision medicine with feedback control
Zlobina, K., Jafari, M., Rolandi, M., & Gomez, M. M. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101149 · Cited by 33
Bassi, M., Patti, L., Silvestrini, I., Strati, M. F., Ponzano, M., Minuto, N., & Maggi, D. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1099024 · Cited by 32
Lynch, J. L., Kanapka, L. G., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., BALLIRO, C. A., Calhoun, P. M., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0341 · Cited by 31
Self-citationJacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 34
Self-citationCordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., MCVEAN, J. J. F., Lee, S. W., Slover, R. H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0123 · Cited by 33
Self-citationRosselot, C., Li, Y., Wang, P., Alvarsson, A., Beliard, K., Lu, G., Kang, R. B., Li, R., Liu, H., Gillespie, V., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3456 · Cited by 30
Haidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jacobs, P. G., Fathi, A. E., Rutkowski, J., Messier, V., & RABASA-LHORET, R. P. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0365 · Cited by 31
Cherubini, V., Rabbone, I., Berioli, M. G., Giorda, S., Presti, D. L., Maltoni, G., Mameli, C., Marigliano, M., Marino, M., Minuto, N., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14491 · Cited by 30
Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data
Toschi, E., Atakov-Castillo, A., Slyne, C., & Munshi, M. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0311 · Cited by 30
The automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 32
Transdermal amperometric biosensors for continuous glucose monitoring in diabetes
Liu, Y., Li, Y., & Cui, Y. (2022) · Talanta · doi:10.1016/j.talanta.2022.124033 · Cited by 29
Pease, A., Zomer, E., Liew, D., Earnest, A., Soldatos, G., Ademi, Z., & Zoungas, S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0064 · Cited by 39
Kanapka, L. G., Lum, J. W., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0548 · Cited by 35
Self-citationInsulin-delivery methods for children and adolescents with type 1 diabetes
Zuberi, Z., Sauli, E., Cun, L., Deng, J., Li, W., He, X.-L., & Li, W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820906016 · Cited by 29
Mansouri, M., & Fussenegger, M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102151 · Cited by 29
Asgharzadeh, A., Patel, M., Connock, M. J., Damery, S. L., Ghosh, I., Jordan, M., Freeman, K., Brown, A., Court, R. A., Baldwin, S., et al. (2024) · Health Technology Assessment · doi:10.3310/jypl3536 · Cited by 32
Bhargava, A., Bergenstal, R. M., Warren, M., Thrasher, J. R., Dempsey, M. A., Bode, B. W., LaRocque, J., Carlson, A. L., Keiter, A., Ma, H., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0586 · Cited by 31
Use of Diabetes Technology in Children
Desrochers, H. R., Schultz, A. T., & Laffel, L. M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.11.001 · Cited by 29
Self-citationBoughton, C. K., & Hovorka, R. (2020) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000786 · Cited by 29
Marks, B. E., Williams, K. M., Sherwood, J. S., & Putman, M. S. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100282 · Cited by 30
Elbarbary, N. S., & Ismail, E. A. R. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110045 · Cited by 31
Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies
Kaur, J., & Seaquist, E. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00762-8 · Cited by 32
Bassi, M., Franzone, D., Dufour, F., Strati, M. F., Scalas, M., Tantari, G., Aloi, C., Salina, A., d’Annunzio, G., Maghnie, M., et al. (2023) · Life · doi:10.3390/life13030783 · Cited by 34
Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population
Alonso, G. T., Triolo, T. M., Aktürk, H. K., PAULEY, M. E., Sobczak, M., Forlenza, G. P., Sakamoto, C., Pyle, L. L., & Frohnert, B. I. (2023) · Diabetes Care · doi:10.2337/dc22-2121 · Cited by 29
Self-citationPaldus, B., Morrison, D., Lee, M., Zaharieva, D. P., Riddell, M. C., & O'Neal, D. N. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088327 · Cited by 32
Thrasher, J. R., Arrieta, A., Niu, F., Cameron, K. R., Cordero, T. L., Shin, J., Rhinehart, A. S., & Vigersky, R. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0453 · Cited by 29
Heterogeneity of glycaemic phenotypes in type 1 diabetes
Fagherazzi, G., Aguayo, G., Zhang, L., Hanaire, H. P., Picard, S., Sablone, L., Vergès, B. L., Hamamouche, N., Detournay, B., Joubert, M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06179-4 · Cited by 30
Ghimire, S., Çelik, T., Gerdes, M. W., & Omlin, C. W. P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310801 · Cited by 31
Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy
Donovan, L., Lemieux, P., Dunlop, A. D., Yamamoto, J. M., Murphy, H. R., Simmons, D., Bell, R. C., Chaput, K. H., Benham, J. L., Ross, G. P., et al. (2025) · JAMA · doi:10.1001/jama.2025.19578 · Cited by 33
Sawyer, A., Sobczak, M., Forlenza, G. P., & Alonso, G. T. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0471 · Cited by 28
Self-citationMichaels, V. R., Boucsein, A., Watson, A. S., Frewen, C. M., Sanders, O. J., Haszard, J. J., Jones, S., Milford-Hughes, P. J., de Bock, M. I., & Wheeler, B. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0334 · Cited by 28
Marks, B. E., Grundman, J., Meighan, S. S., Monaghan, M. C., Streisand, R. M., & PERKINS, A. G. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0450 · Cited by 27
De Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06366-x · Cited by 27
Jacobsen, L. M., & Schatz, D. (2026) · JAMA · doi:10.1001/jama.2026.0048 · Cited by 30
Irace, C., Cutruzzolà, A., Nuzzi, A., Assaloni, R., Brunato, B., Pitocco, D., Tartaglione, L., Molfetta, S. D., Cignarelli, A., Laviola, L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13993 · Cited by 28
Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses
Nimri, R., Grosman, B., Roy, A., Nir, J., Fisch-Shvalb, N., Kurtz, N., Loewenthal, N., Gillon‐Keren, M., Muller, I., Atlas, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0448 · Cited by 28
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement
Scott, S. N., Fontana, F. Y., Cocks, M. S., Morton, J. P., Jeukendrup, A. E., Dragulin, R., Wojtaszewski, J. F. P., Jensen, J., Castol, R., Riddell, M. C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00054-1 · Cited by 31
Opportunities and challenges in closed-loop systems in type 1 diabetes
Wilson, L. M., Jacobs, P. G., Riddell, M. C., Zaharieva, D. P., & Castle, J. R. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00289-8 · Cited by 27
Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review
Karol, A. B., O’Malley, G., Fallurin, R., & Levy, C. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.001 · Cited by 27
Self-citationStawarz, K., Katz, D., Ayobi, A., Marshall, P., Yamagata, T., Santos‐Rodríguez, R., Flach, P. A., & O’Kane, A. A. (2023) · International Journal of Human-Computer Studies · doi:10.1016/j.ijhcs.2023.103003 · Cited by 27
Baker, M., Musselman, M. E., Rogers, R., & Hellman, R. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab456 · Cited by 27
Closed-loop systems: recent advancements and lived experiences
Kadiyala, N., Hovorka, R., & Boughton, C. K. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2406901 · Cited by 29
Jafar, A., Fathi, A. E., & Haidar, A. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.105936 · Cited by 27
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
